anandamide (ATC-001) / Atticus Pharma - LARVOL DELTA

Atticus Pharma Awarded $2 Million NIH Phase II SBIR Grant to Advance Cutaneous Lupus Drug Candidate (Atticus Press Release) - "The grant will support further development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus, building on positive data from multiple animal models of lupus that showed resolution of lesions and dramatic improvements in skin and histopathology scores."

Financing • Cutaneous Lupus Erythematosus